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Introduction: Molecular diagnosis of hereditary breast and ovarian cancer (HBOC) has been 
mostly based on the identification of germline inactivating mutations in the high-penetrant genes 
BRCA1 and BRCA2. Although several other HBOC susceptibility genes have been identified, 
mutations in any of those are rare, rendering sequential genetic testing with standard 
methodologies time consuming and expensive. Next-generation sequencing (NGS) gene panels 
allow the simultaneous sequencing of multiple HBOC susceptibility genes at a lower cost.  The 
aim of this work was to validate the use of an NGS cancer susceptibility gene panel for the 
identification of mutations previously detected by Sanger sequencing in the BRCA1, BRCA2 
and TP53 genes. 
Methods: 20 samples from patients with personal/family history of breast cancer were 
sequenced on a MiSeq using the Trusight Cancer Sequencing Panel (Illumina). Bioinformatic 
analysis of NGS data included the MiSeq Reporter, VariantStudio and Isaac Enrichment tools 
(Illumina).  
Results: NGS successfully identified all 204 variants (38 unique, including 2 deletions and a 
splice variant) previously detected by Sanger sequencing in the BRCA1, BRCA2 and TP53 
genes. Until now, no false-negative or false-positive results were obtained. 
Discussion: These results demonstrate the high analytical sensitivity and specificity obtained 
with NGS for the detection of sequence variants in 3 HBOC high-penetrant genes.  These 
validation assays open the way to the definition of a clinically useful multigene panel for HBOC 
susceptibility based on the Trusight Cancer Sequencing Panel. This will allow a comprehensive 
and cost-effective molecular diagnosis of HBOC with a shorter turnaround time when compared 
to standard methodologies. In addition, with appropriate genetic counselling and specialized 
clinical surveillance, families with HBOC will benefit from these new technologies which have 
high impact in public health.   
 
 
 
 
